Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
601-620 of 1,738 trials

Frontotemporal Dementia: DNL593 Study

We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.

Frontotemporal Dementia1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Gastrointestinal Cancers: MK-2870 Treatment Study

We are testing the safety and effectiveness of MK-2870, alone or with other cancer treatments, for people with gastrointestinal cancers. This study aims to see how well it works in reducing tumors and improving patient outcomes.

Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, and Biliary Tract Cancer6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: Neoadjuvant Triple Treatment Study

We are exploring a new combination of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer. The goal is to see if this treatment improves survival and surgical outcomes.

Pancreatic CancerBorderline Resectable Pancreatic Cancer (BRPC)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Progressive Supranuclear Palsy: 18F-PI-2620 PET Imaging Study

We are investigating a new imaging tool to help identify and understand progressive supranuclear palsy in patients. This study may improve diagnosis and treatment options for this rare neurological condition.

Parkinson's DiseaseProgressive Supranuclear Palsy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

Vulvar Cancer: Chemoradiation Study

We are investigating if chemoradiation alone is a safe alternative to surgery for early-stage vulvar cancer patients with lymph node involvement. The study also evaluates the side effects of this treatment over time.

Vulvar Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Metastatic Colorectal and Gastroesophageal Cancer: Trifluridine/Tipiracil Study

We are studying the safety of Trifluridine/tipiracil as a new chemotherapy for patients with metastatic colorectal or gastroesophageal cancer who have a specific genetic deficiency. This trial aims to see if it can be a safer alternative to traditional treatments.

Metastatic Colon or Rectal Cancer with DPD Deficiency1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Breast Cancer: GR1014 Gel for Radiation Skin Protection

We are studying whether GR1014 gel can help prevent skin damage during radiation therapy for localized breast cancer after lumpectomy. This trial compares the gel to a standard treatment to see which is more effective.

Radiation-Induced Dermatitis≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesDermatologyOncology

Advanced Non-Small Cell Lung Cancer: New Immunotherapy Combinations

We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: Cemiplimab Immunotherapy Study

We are investigating if continuing cemiplimab treatment helps patients with oligometastatic NSCLC live longer without disease progression after initial therapy. This study compares the effects of cemiplimab to a placebo.

Non-small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Standard MedicinesOncology

Erosive Esophagitis: Oral Pantoprazole for Kids and Teens

We are studying how well oral pantoprazole works for maintaining healing in children and teens aged 1 to 17 with erosive esophagitis. We also want to understand its safety and how well they tolerate the treatment.

Erosive Esophagitis6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteGastroenterologyPediatrics

Triple-Negative Early Breast Cancer: Sacituzumab Govitecan with or without Pembrolizumab

We are comparing two treatment options for low-risk, triple-negative early breast cancer to see which is more effective. The study also evaluates how these treatments affect patients' quality of life.

Triple-Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Epidermolysis Bullosa Simplex: Apremilast Study

We are investigating whether apremilast can improve symptoms in patients over 6 years old with epidermolysis bullosa simplex. The study will also look at the safety of the treatment and how it affects quality of life.

Epidermolysis Bullosa Simplex3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyRheumatology

Refractory Focal Onset Epilepsy: BHV-7000 Study

We are testing a new medication, BHV-7000, to see if it can help reduce seizures in adults with refractory focal onset epilepsy. The study compares its effects to a placebo to evaluate safety and effectiveness.

Focal Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

BHV-7000 for Idiopathic Generalized Epilepsy

We are studying a new treatment for people with idiopathic generalized epilepsy who have generalized tonic-clonic seizures. The trial will compare its effects to a placebo to see if it helps reduce seizure frequency and is safe to use.

Idiopathic Generalized Epilepsy6-12 monthsEfficacy phase (II)Confirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Refractory Focal Onset Epilepsy: BHV-7000 Safety Study

We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.

Focal Epilepsy1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Epidermolysis Bullosa Simplex: Diacerein 1% Ointment

We are studying a new ointment for people with generalized Epidermolysis Bullosa Simplex to see if it helps improve skin condition and reduce symptoms. The trial includes both adults and children aged 6 months and older.

Epidermolysis Bullosa Simplex1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Diabetic Kidney Disease: Hyperpolarized MRI Study

We are investigating a new MRI technique to see if it can help classify the progression of diabetic kidney disease. This study aims to improve understanding of kidney function and metabolism in affected individuals.

Diabetic Kidney Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyNephrology

Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Treatment Study

We are studying a new treatment approach for patients with resectable non-small cell lung cancer to see if it improves tumor response and safety before and after surgery.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Myeloid Malignancies: BGB-11417 Study

We are testing a new drug, BGB-11417, in combination with azacitidine for patients with myeloid malignancies. The goal is to find the safest dose and see how well it works against the disease.

Myeloid MalignanciesSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Diabetic Retinopathy: BI 764524 Treatment Study

We are testing whether the new treatment BI 764524 can improve eye health in people with diabetic retinopathy. The study will compare its effects to a placebo to see if it helps prevent serious vision problems.

Diabetic Retinopathy6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesEndocrinologyOphthalmology